Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003840 · ClinicalTrials.gov registry record · Phase 1
DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003840 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences.
The verdict
NCT00003840, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: DTGM fusion protein may be able to locate cancer cells and stop them from growing. PURPOSE: Phase I/II trial to study the effectiveness of DTGM fusion protein in treating patients who have recurrent or refractory acute myeloid leukemia.
Interventions
- BIOLOGICAL DTGM fusion protein
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2005-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003840
The ClinicalTrials.gov registry entry for NCT00003840 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DTGM fusion protein is the first listed.
NCT00003840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003840 about?
NCT00003840 is a clinical study titled "DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia". RATIONALE: DTGM fusion protein may be able to locate cancer cells and stop them from growing. PURPOSE: Phase I/II trial to study the effectiveness of DTGM fusion protein in treating patients who have recurrent or refractory acute myeloid leukemia.
What is the current status of trial NCT00003840?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-10. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00003840?
The interventions under investigation include: DTGM fusion protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003840?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.